Reinventing Vision Screening.

We are building the world’s most comprehensive, self-administered, ultra-portable ocular screening device—enabling rapid risk stratification of leading causes of blindness.
Self-administered
No space constraints
Immediate Results
Our Value Proposition

ETDRS.

The only device in the world at the moment to support complete Early Treatment of Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart in a device.*

Self-administered & Remote-Testing.

Designed for patient-led assessments, improving accessibility and convenience. Proven to increase testing capacity exponentially.

Significant Cost-savings of 95.3% per test.

Proven to reduce ETDRS test costs by 95.3%, making vision screening care more affordable.**

Comprehensive.

Screens for cataracts, glaucoma, macular degeneration, and other leading causes of blindness in a single device.***

Leaders in vision care

We are the leaders for vision care screening.

Our goal is to transform global eye care by providing innovative, accessible, and cost-effective solutions that empower early detection and management of vision-threatening conditions.

Our Partners
How it works

White Paper

Building the world’s first Augmented Reality Vision Screening Device. (Coming Soon)
  • Glass, Moon Technologies Pte. Ltd.’s device is a Class A certified Medical Device as authorised by Health Science and Authority (HSA).

  • Cost-savings are based on clinical trials with Tan Tock Seng Hospital. Comparisons were made between current standard methodologies and our device in performing 400 ETDRS eye tests.

  • At present, the device is limited to ETDRS functionality. Screening for other conditions is currently undergoing clinical validation.

  • Glass, Moon Technologies Pte. Ltd.’s device is a Class A certified Medical Device as authorised by Health Science and Authority (HSA).